Insulet Corporation (PODD) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in [url="]tubeless insulin pump technology[/url] with its Omnipod brand of pro
ACTON, Mass.--(BUSINESS WIRE)--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet earns a short-term Hold as outlook rises; a $163 sales-based target tests whether growth can beat 2026 volatility.
A U.S. ‌appeals court on Thursday overturned a $452 million verdict that ​medical device maker ​Insulet won against Korean rival ⁠EOFlow for allegedly ​stealing trade secrets related ​to i
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will pres
Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.

Stock Futures Higher as Micron Stock Extends Rally

09:05am, Wednesday, 27'th May 2026
Stock futures are firmly higher as Micron Technology (MU) stock extends its rally
Insulet said on Tuesday it is carrying out a voluntary correction of certain insulin pump pods across ​its Omnipod product lines after identifying a manufacturing ‌issue that could result in patie
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omn
On May 18, 2026, Insulet Corp (PODD) shares rose 3.5% to a current price of $152.49. Over the past 52 weeks, the stock has fluctuated between a high of $354.88
Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Insulet: An Opportune Time To Get Involved

11:04am, Wednesday, 13'th May 2026
Insulet delivered robust Q1 2026 results, with revenue up 34% to $762M and operating margins expanding to 17.5%. Insulet raised full-year guidance to 21-23% sales growth and expects adjusted earnings
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE